Clinical Cardiology Alert – March 1, 2020
March 1, 2020
View Issues
-
Heart Rate and Diastolic Blood Pressure in Chronic Aortic Regurgitation Patients
A retrospective observational study of patients with moderate to severe aortic regurgitation showed the independent predictive value of diastolic blood pressure and resting heart rate for all-cause mortality under medical management.
-
Rivaroxaban After Transcatheter Aortic Valve Replacement
In this randomized trial of post-transcatheter aortic valve replacement patients without a separate indication for anticoagulation, a rivaroxaban-based approach was associated with a higher risk of death and thromboembolic complications compared with dual antiplatelet therapy.
-
Home Oral Factor Xa Inhibitor Treatment for Pulmonary Embolism
Low-risk pulmonary embolus patients discharged in < 48 hours on rivaroxaban recorded a nominal three-month rate of recurrent emboli or major bleeding, suggesting such patients do not need to be hospitalized for treatment of pulmonary emboli.
-
Heart Failure-Exacerbating Medications
In a large, diverse cohort of Medicare patients hospitalized for heart failure exacerbations, almost half were on medications known to exacerbate heart failure; more than one-third were on these agents at discharge.
-
Efficacy of Class I vs. Class III Antiarrhythmic Drugs in Obese Patients
In an observational cohort of patients with atrial fibrillation, obese patients were less likely than nonobese patients to avoid symptomatic recurrence on sodium channel blocking agents in contrast to a roughly equivalent response in both groups to potassium channel blocking agents.